July 22, 2019 10:22 AM EDT

Takeda reports second PhIII win for subcutaneous Entyvio as regulators review expanded use

Amber Tong

Before consummating its $62 billion buyout of Shire, Takeda divested SHP647 — which the rare disease biotech was developing for ulcerative colitis — so it can …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Takeda reports second PhIII win for subcutaneous Entyvio as regulators review expanded use

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

Small personalized vaccine trial sees progress in late-stage kidney cancer

GSK defiant against vaccine challenges, will prioritize other growth areas

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

Kura's AML drug passes key study in advanced patients, plans next steps with FDA and newly diagnosed studies

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Take­da re­ports sec­ond PhI­II win for sub­cu­ta­neous En­tyvio as reg­u­la­tors re­view ex­pand­ed use

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Takeda reports second PhIII win for subcutaneous Entyvio as regulators review expanded use